Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Low affinity immunoglobulin gamma Fc region receptor II-b (FCGR2B, also known as CD32B) is a type I transmembrane glycoprotein and the sole inhibitory receptor within the Fc gamma receptor (FcγR) family. It is widely expressed on B cells, dendritic cells, macrophages, and other myeloid cells, where it plays a critical role in maintaining immune homeostasis and preventing autoimmunity. Upon co-engagement with the B-cell receptor (BCR) or activating Fc receptors by immune complexes, FCGR2B undergoes phosphorylation of its cytoplasmic immunoreceptor tyrosine-based inhibition motif (ITIM), recruiting phosphatases like SHIP1/2 to downregulate cell activation, antibody production, and phagocytosis.
In oncology, high expression of FCGR2B on tumor cells is associated with resistance to monoclonal antibody therapies (such as rituximab) by promoting antibody internalization and degradation. Consequently, therapeutic strategies targeting FCGR2B include antagonistic antibodies (e.g., BI-1206, BI-1607) to overcome drug resistance in B-cell malignancies and solid tumors, as well as bifunctional antibodies (e.g., obexelimab) that co-engage CD19 and FCGR2B to suppress B-cell activity in autoimmune and inflammatory diseases.
Monoclonal antibodies targeting FCGR2B (CD32B) act either as antagonists to block its inhibitory signaling, thereby enhancing the efficacy of other therapeutic antibodies (such as rituximab or pembrolizumab) by preventing target internalization and restoring antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP), or as bifunctional agents (e.g., co-targeting CD19) that co-engage the B-cell receptor complex and FCGR2B to trigger intracellular ITIM-mediated inhibitory pathways (via SHIP1/2 recruitment) and suppress B-cell activation without depleting the cells.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Low affinity immunoglobulin gamma Fc region receptor II-b (FCGR2B).